Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of GBX 5.25 and traded as low as GBX 2.93. Shield Therapeutics shares last traded at GBX 3.05, with a volume of 41,407,309 shares changing hands.
Shield Therapeutics Price Performance
The company’s 50 day moving average price is GBX 5.25 and its 200-day moving average price is GBX 6.96. The company has a market cap of £35.34 million, a price-to-earnings ratio of -3.29 and a beta of 1.77. The company has a debt-to-equity ratio of -146.28, a quick ratio of 2.16 and a current ratio of 0.75.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
